Non-adherence to prescribed therapy has long been a serious issue that may lead to detrimental consequences for patient outcomes. Indeed, an alarming number of patients with chronic conditions never even initiate their prescribed therapy. For instance, up to half of patients diagnosed with hyperlipidemia and nearly a third of those with HIV don’t fill their prescriptions,1 while those that do, too often discontinue use in the first year of treatment.
The need to assess patients’ lab values prior to initiating therapy, or to monitor them over the course of therapy, is one more hurdle that exacerbates an already intractable problem. Traveling to a clinic to have blood drawn deters many patients from initiating and adhering to their therapy in the best of times, but now, this is especially onerous due to the impact of the COVID-19 pandemic as individuals may be required to shelter in place.
Accessing in-home phlebotomy services, frequently used in decentralized clinical trials, is one solution to make it easier for patients during the pandemic and beyond.
With IQVIA’s latest in-home phlebotomy services, nurses or phlebotomists can easily be deployed to support patients who are prescribed drugs for which blood draws or laboratory workups are requisite clinical standards. Our in-home phlebotomy services are structured to connect the multiple parties involved in the blood collection and analysis process.
The IQVIA program is designed to support specific prescriptions and is not a general phlebotomy service that physicians can request outside of the contract parameters; only the labs that are in the PI are to be ordered. To ensure that its service complies with all regulations and medical standards, it is structured so that
By utilizing IQVIA’s remote phlebotomy services, pharmaceutical companies can better support prescription adherence by ensuring patients receive and continue with their prescribed therapy by removing the laboratory access barrier. To learn more, contact us.
1 Final % claims not paid (1H20), IQVIA LAAD Claims Data.